Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

GH treatment stimulates growth in short children with juvenile idiopathic arthritis (JIA).

Who Took Part

The study group was 13 patients.

PubMed indexes the participants as young children and children, both men and women.

Thirty-one growth-retarded children with systemic and polyarticular idiopathic arthritis were enrolled in this controlled study.

Eighteen patients (12 females and six males) served as an untreated control group.

How the Study Was Run

The design is described as randomized.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Arthritis, Juvenile, Body Height, Growth, Growth Hormone, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Sex Characteristics.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 13 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.